Zusammenfassung
In bis zu 60% der Fälle kann ein atopisches Ekzem bis in das Erwachsenenalter persistieren und durch besondere klinische Manifestationen und Verlaufsformen gekennzeichnet sein. Die Einführung der topischen Calcineurininhibitoren Pimecrolimus-1%-Creme und Tacrolimus-0,03%- und -0,1%-Salbe wird, wie umfangreiche klinische Studien und die zunehmende praktische Erfahrung zeigen, das Langzeitmanagement des atopischen Ekzems mittelschwerer Ausprägung bei Erwachsenen deutlich verbessern. Die topischen Calcineurininhibitoren sind auch bei Anwendung über Wochen und Monate sicher, verträglich und wirksam, bessern rasch den Juckreiz und ermöglichen—wie vor allem Studien mit der Pimecrolimus-1%-Creme gezeigt haben—eine signifikante Verlängerung der schubfreien Zeit mit Reduktion oder weitgehender Vermeidung einer zusätzlichen Anwendung von topischen Kortikosteroiden.
Abstract
In about 60% of cases, atopic eczema can persist in adulthood with distinctive clinical features and disease course. The introduction of the topical calcineurin inhibitors pimecrolimus 1% cream and tacrolimus 0,03 and 0,1% ointment clearly improves the long-term management of atopic eczema in adult patients; this has been shown in several large clinical studies and is confirmed by the growing practical experience with these substances. Topical calcineurin inhibitors are, even when applied for weeks and months, safe, well tolerated and efficient; they have a rapid and positive effect on pruritus and the potential—as shown in clinical studies with pimecrolimus 1% cream—to reduce the number of eczema flares, to significantly prolong the time to a first flare and to reduce or even eliminate the need for topical corticosteroids.
Literatur
Hill CH, Sulzberger MB (1935) Evolution of atopic dermatitis. Arch Dermatol Syph 32:451–463
Kissling S, Wütherich B (1993) Verlauf der atopischen Dermatitis nach dem Kindesalter. Hautarzt 44:569–573
Rystedt I (1985) Hand eczema and long-term prognosis in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 117:1–59
Kissling S, Wüthrich B (1994) Lokalisationen, Manifestationstypen sowie Mikromanifestationen der atopischen Dermatitis bei jungen Erwachsenen. Eine persönliche Nachkontrolle 20 Jahre nach Diagnosestellung im Kindesalter. Hautarzt 45:368–371
Herzberg J (1973) Wenig bekannte Formen der Neurodermitis. Hautarzt 24:47–51
Vickers CFH (1980) The natural history of atopic eczema. Acta Derm Venereol Suppl 92:113–115
Burrows D, Penman RWB (1960) Prognosis of the eczema-asthma syndrome. Br J Med 2:825–828
Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG (1994) The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol 30:35–39
Leent EJM van, Gräber M, Thurston M et al. (1998) Effectiveness of the Ascomycin Macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 134:805–809
Luger T, Leent EJM van, Graeber M et al. (2001) SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 144:788–794
Meurer M, Fölster-Holst R, Wozel G et al. (2002) Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 205:271–277
Wahn U, Bos JD, Goodfield M et al. (2002) Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 110:e2
Kapp A, Papp K, Bingham A et al. (2002) Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J Allergy Clin Immunol 110:277–284
Meingassner JG, Stütz A (1992) Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 98:851–855
Bekersky I, Fitzsimmons W, Tanase A et al. (2001) Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 44:7–27
Ruzicka T, Bieber T, Schopf E et al. (1997) A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 337:816–821
Wollenberg A, Sharma S, Bubnoff D von et al. (2001) Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dematitis. J Allergy Clin Immunol 107:519–525
Remitz A, Kyllönen H, Granlund H, Reitamo S (2001) Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 107:196–197
Queille-Roussel C, Paul C, Duteil L et al. (2001) The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 144:507–513
Reitamo S, Rissanen J, Remitz A et al. (1998) Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 111:396–398
Reitamo S, Wollenberg A, Schopf E et al. (2000) Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Study Group. Arch Dermatol 136:999–1006
Reitamo S, Rustin M, Ruzicka T et al. (2002) Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 109:547–555
Sugiura H, Uehara M, Hoshino N, Yamaji A (2002) Long-term efficacy of tacrolimus (FK506) ointment for facial erythema in atopic dermatitis patients: an analysis of their backgrounds compared with response to tacrolimus ointment. In: Tsambaos D, Merk H (eds) Modern trends in skin pharmacology. Parissianos Medical Publications, pp 329–335
Caro I, Gordon KB, Sheehan M et al. (2002) Long-term safety of topically applied tacrolimus ointment in adult patients with atopic dermatitis. Poster presentation. 60th Annual Meeting Am Acad Dermatol, New Orleans, Febr 22–27
Allen A, Siegfried E, Silverman R et al. (2001) Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 137:747–750
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Meurer, M., Wozel, G. Behandlung des atopischen Ekzems bei Erwachsenen mit topischen Calcineurininhibitoren. Hautarzt 54, 424–431 (2003). https://doi.org/10.1007/s00105-003-0526-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-003-0526-1